Taking an important step towards the treatment of diabetes in India, pharmaceutical company Cipla has announced the launch of orally (inhalable) insulin powder. The company said on Monday that it has introduced this rapid-acting orally inhaled insulin named Afrezza in the country, which provides a needle-free and convenient alternative to traditional injection-based insulin therapy.

This step of Cipla is being considered important towards further modernizing the methods of diabetes treatment in India.

Lifestyle of diabetic patients can become easier

According to the company, it had received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) late last year for the exclusive distribution and marketing of Afrezza. Now with its launch, a new option has become available in the treatment of diabetes in India.

Cipla said that the launch of this product in India is expected to benefit about 10 crore people suffering from diabetes in the country. For diabetic patients, taking insulin injections daily is not only physically but also mentally challenging, in such a situation, inhalable insulin can make the lifestyle of the patients easier.

How does inhalable insulin work?

The insulin inhalation powder in Afrezza is available in single-use cartridges, which are taken through a special inhaler device. Its process is very simple. The patient first has to choose the cartridge as per the dosage prescribed by the doctor, insert it into the inhaler and then inhale the insulin from the device. The cartridge is discarded after use.

This insulin is usually started with the largest meal of the day and the dose can be increased as needed. This is a fast-acting insulin, which helps in controlling blood sugar after meals.

What does the company say

Achin Gupta, Global Chief Operating Officer, Cipla, said that this innovation not only makes insulin delivery easier, but also reduces the emotional and practical hassles that patients have to face while taking daily injections. He said that this step is an important initiative towards improving the quality of life of diabetes patients.

Status of company shares

Cipla shares closed at ₹ 1,512.50 in the stock market on Monday, which shows a slight decline of 0.30% compared to the previous session. The company's 52-week high has been ₹ 1,672.20 and low ₹ 1,310.05. The market capitalization of Cipla is around ₹ 1.22 lakh crore.

Disclaimer: newshimachali does not advise investing in any stock, mutual fund, IPO. Only information about stocks is given here. Before investing, definitely take the advice of your financial advisor.